Americans are paying more for prescription drugs than anyone else in the world. The same medicine that sells for a fraction of the price overseas can cost ten times as much here at home.
This week, President Trump announced the first-ever deal to bring Most Favored Nation pricing to American patients. The principle is simple: if a drug company sells medicine cheaper abroad, American patients should get that same deal. It’s a bold move that sends a clear signal—we must put patients before profits.
Now, I’ll be the first to say: price controls are a tricky tool. They can create distortions and unintended consequences if done poorly. But here’s the bottom line—the President is doing what he can. He’s moving the ball forward while Congress refuses to take the field.
For years, Congress has been absent in this fight. Instead of acting to lower costs, too many members have cashed checks from the pharmaceutical and health industry. My opponent, Rep. Ann Wagner, has taken millions from Big Pharma alone.
And let’s not kid ourselves—these corporations are not working in your best interest. Their business model depends on extracting wealth from sick Americans, even as families ration life-saving medications.
That’s why this isn’t just about one policy or one executive order. It’s about who Congress is working for. Right now, Congress is working for the corporations. It should be working for the American patient.
If we truly believe in America First, then we must put patients first. That means real legislative reforms: transparency, competition, generics, breaking up monopolistic practices, and cutting the red tape that protects corporate middlemen while driving up costs.
The President can only do so much from the White House. The heavy lifting must come from Congress. And if we’re serious about fixing this broken system, then we need new leadership in Washington—leadership that will stand up to Big Pharma and put the American patient back at the center of our healthcare system.
Because health care should heal—not bankrupt